Attached files
file | filename |
---|---|
EX-32.2 - EXHIBIT 32.2 - Ocuphire Pharma, Inc. | ex32_2.htm |
EX-32.1 - EXHIBIT 32.1 - Ocuphire Pharma, Inc. | ex32_1.htm |
EX-31.2 - EXHIBIT 31.2 - Ocuphire Pharma, Inc. | ex31_2.htm |
EX-31.1 - EXHIBIT 31.1 - Ocuphire Pharma, Inc. | ex31_1.htm |
EX-24.1 - EXHIBIT 24.1 - Ocuphire Pharma, Inc. | ex24_1.htm |
EX-12.1 - EXHIBIT 12.1 - Ocuphire Pharma, Inc. | ex12_1.htm |
10-K - REXAHN PHARMACEUTICALS 10-K 12-31-2016 - Ocuphire Pharma, Inc. | form10k.htm |
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We hereby consent to the incorporation by reference in the Registration Statements on Form S-3 (Nos. 333-196255 and 333-175073) and Form S-8 (Nos. 333-189240 and 333-129294) of Rexahn Pharmaceuticals, Inc., of our reports dated February 24, 2017, relating to the financial statements and the effectiveness of Rexahn Pharmaceuticals, Inc.’s internal control over financial reporting, which appear in this Form 10-K.
/s/ Baker Tilly Virchow Krause, LLP
Wyomissing, Pennsylvania
February 24, 2017